“This agreement between the cities of Seattle and Shenzhen will encourage and support meaningful cooperation between two global leaders of innovation in medical research and technology,” Mr. Murray said in a statement. “Ultimately, it will create new opportunities for our biotech and healthcare industries and help advance pioneering medical technology that will benefit patients, doctors and communities around the globe.”
The collaboration was forged in a memorandum that also includes trade delegations between Seattle and two other Chinese cities, Hong Kong and Hangzhou.
The genomics research will focus on the use of next-generation sequencing in population health and personalized care. This spans methods of collection, storage, sharing and analysis for genetic information like DNA. The two institutions also plan to collaborate on the joint development of a Seattle-Shenzhen Institute with research outposts in each city.
More articles on genomics:
2 Google and Twitter executives create genetic cancer testing startup
New technology eases adoption of precision medicine initiative
Intermountain, Stanford establish research program focused on precision health: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
